NUZNEURIZON THERAPEUTICS LIMITED

Announcement history available from 1 August 2025

Fromto

Date / Time	Title	Type	MS	Report Codes
13 Aug 2026, 19:46	Elanco representative appointed as Neurizon Board Observer	Company Administration	—	12008
11 Aug 2026, 19:47	Neurizon Completes Initial Drawdown under R&D Facility	Capital Raising	—	03022
1 Aug 2026, 01:32	Appendix 4C & Quarterly Update	Quarterly Reports	MS	19004, 19009
1 Aug 2026, 01:21	Neurizon Enters Strategic R&D Financing Facility	Capital Raising	MS	03022
29 July 2026, 23:56	Melbourne investor briefing presentation	Presentations	—	03026
17 July 2026, 19:25	HEALEY Enrolment Complete - Topline Accelerated to Q2 CY27	Company Update	MS	11001
16 July 2026, 21:39	Application for quotation of securities - NUZ	Other	—	06020
15 July 2026, 02:36	Notification of cessation of securities - NUZ	Other	—	06027
2 July 2026, 19:20	Neurizon Invites Investors to Melbourne Briefing	Company Administration	—	12008
1 July 2026, 19:48	Change of Director's Interest Notice	Director Interests	—	02009
30 June 2026, 19:13	Proposed issue of securities - NUZ	Securities Administration	—	06013
30 June 2026, 02:31	Notification of cessation of securities - NUZ	Other	—	06027
23 June 2026, 21:25	New NUZ-001 Mechanistic Data Presented at BIO 2026	Company Update	—	03026, 11001
19 June 2026, 21:15	Application for quotation of securities - NUZ	Other	—	06020
17 June 2026, 19:07	Neurizon executes long-term supply agreement with Elanco	Company Update	MS	11001
12 June 2026, 19:07	HEALEY ALS Trial Surpasses 50% Dosing Ahead of Schedule	Company Update	MS	11001
3 June 2026, 03:32	Application for quotation of securities - NUZ	Other	—	06020
29 May 2026, 01:24	Webinar presentation - Regimen I expands to 240 participants	Presentations	—	03026, 14014
27 May 2026, 19:20	HEALEY ALS Trial Regimen I Expands to 240 Participants	Company Update	MS	11001
13 May 2026, 19:19	Ethics Approval Received for NUZ-001 Oral Liquid P1 Study	Company Update	MS	11001
13 May 2026, 02:27	Final Director's Interest Notice	Director Interests	—	02010
13 May 2026, 02:22	Initial Director's Interest Notice	Director Interests	—	02008
11 May 2026, 23:20	Australian Microcap Investment Conference Presentation	Presentations	—	03026
8 May 2026, 19:06	Neurizon Strengthens Board for the Next Growth Phase	Company Administration	—	12001, 12008
4 May 2026, 22:15	Change of Director's Interest Notices	Director Interests	—	02009
1 May 2026, 02:17	Neurizon investor briefing presentation	Presentations	—	03026
1 May 2026, 02:09	Application for quotation of securities - NUZ	Other	—	06020
30 Apr 2026, 19:38	Appendix 4C & Quarterly Update	Quarterly Reports	MS	19003, 19008
21 Apr 2026, 19:40	Section 708A Cleansing Statement	Securities Administration	—	06018
21 Apr 2026, 19:33	Application for quotation of securities - NUZ	Other	—	06020
17 Apr 2026, 00:30	Neurizon Investor Briefings Invitation	Company Administration	—	12008
16 Apr 2026, 19:28	Placement of Entitlement Offer Shortfall	Capital Raising	MS	06008
10 Apr 2026, 19:58	Investor Presentation - April 2026	Presentations	—	03026
2 Apr 2026, 03:39	Section 708A Cleansing Statement	Securities Administration	—	06018
2 Apr 2026, 03:25	Application for quotation of securities - NUZ	Other	—	06020
1 Apr 2026, 20:46	NUZ-001 Data Shows Multi-Pathway Protein Clearance	Company Update	MS	11001
26 Mar 2026, 19:18	Change of Director's Interest Notices x4	Director Interests	—	02009
20 Mar 2026, 20:48	Notification of Expiry of NUZOA Listed Options	Letters & Addresses	—	06009, 16001
20 Mar 2026, 19:40	Neurizon presents at HEALEY ALS Platform Trial Webinar	Presentations	—	03026
19 Mar 2026, 22:37	Section 708A Cleansing Statement	Securities Administration	—	06018
19 Mar 2026, 22:16	Application for quotation of securities - NUZ	Other	—	06020
16 Mar 2026, 19:19	Neurizon announces leadership transition	Other	MS	12017, 12019
5 Mar 2026, 21:13	Preclinical Data in Huntington's Disease Presented at ASENT	Company Update	—	03026, 11001
4 Mar 2026, 19:33	Notification of cessation of securities - NUZ	Other	—	06027
28 Feb 2026, 03:49	Drawdown of tranche one of strategic financing facility	Capital Raising	—	03022
28 Feb 2026, 03:34	Notification regarding unquoted securities - NUZ	Other	—	06021
27 Feb 2026, 20:56	Cleansing Statement - Section 708A(12C)(e)	Securities Administration	—	06018
27 Feb 2026, 20:32	Application for quotation of securities - NUZ	Other	—	06020
27 Feb 2026, 20:27	Section 708A Cleansing Statement	Securities Administration	—	06018
26 Feb 2026, 20:10	Neurizon Initiates Dosing in HEALEY ALS Platform Trial	Company Update	MS	11001

1–50 of 113

Rows

1 / 3